This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may speed up how quickly your liver processes your cancer medicine.
What might happen:
The amount of your cancer medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to adjust the dose of your cancer medicine or change you to a medicine that does not interact with your cancer medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Inlyta (axitinib) US prescribing information. Pfizer Inc. August, 2014. 2.Cotellic (cobimetinib) US prescribing information. Genentech, Inc. May, 2016.
2.Lynparza (olaparib) US prescribing information. AstraZenica Pharmaceuticals October, 2016.
3.Ibrance (palbociclib) US prescribing information. Pfizer Labs February 3, 2015.
4.Odomzo (sonidegib) US prescribing information. Novartis Pharmaceuticals May, 2016.
5.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
6.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
7.Dirix L, Swaisland H, Verheul HM. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. Clin Ther 2016 Oct; 38(10):2286-2299.